placebo vehicle gel

DRUG4 trials

Sponsors

Integra LifeSciences Corporation, University of California, San Francisco, Oya Helin Dundar

Conditions

Acne VulgarisAlcohol-Related DisordersAldehyde Dehydrogenase DeficiencyDiabetic Foot UlcersFlushing

Early Phase 1

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

CompletedNCT03497442

University of California, San FranciscoAlcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency, Flushing

Start: 2018-07-12End: 2019-03-25Updated: 2020-05-04

Phase 3

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

TerminatedNCT01830348

Integra LifeSciences CorporationDiabetic Foot Ulcers

Start: 2013-02-28End: 2015-12-31Updated: 2017-12-12

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

TerminatedNCT01849965

Integra LifeSciences CorporationDiabetic Foot Ulcers

Start: 2013-04-30End: 2015-12-31Updated: 2017-12-12

Phase 4

Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris

Enrolling by invitationNCT07244887

Oya Helin DundarAcne Vulgaris

Start: 2025-06-17End: 2026-08-31Target: 100Updated: 2025-12-05

Related Papers

Effect of Topical Brimonidine on Alcohol-Induced Flushing in Asian Individuals

JAMA Dermatology2019-12-047 citations

NorLeu<sup>3</sup>-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers.

2015-06-0120 citations